{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:53:50Z","timestamp":1783338830476,"version":"3.54.6"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.diagmicrobio.2021.115553","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T14:48:04Z","timestamp":1632494884000},"page":"115553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["In vitro activity of ceftazidime-avibactam and comparators against bacterial isolates collected in South Korea as part of the ATLAS global surveillance program (2016\u20132018)"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-2271","authenticated-orcid":false,"given":"In-Gyu","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0001","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1128\/AAC.00897-16","article-title":"Interaction of avibactam with Class B metallo-\u03b2-lactamases","volume":"60","author":"Abboud","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0003","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0004","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2020"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0005","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0006","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. http:\/\/www.eucast.org. Accessed 22 June 2021."},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0007","unstructured":"FDA-Identified Interpretive Criteria. Tigecycline injectable products. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/tigecycline-injection-products. Revised 17 June 2019. Accessed 22 June 2021."},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12941-020-00355-1","article-title":"In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015\u20132017)","volume":"19","author":"Ko","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jgar.2019.07.003","article-title":"Longitudinal analysis of the in vitro activity of ceftazidime\/avibactam versus Enterobacteriaceae, 2012\u20132016","volume":"19","author":"Ramalheira","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijid.2019.11.006","article-title":"Antimicrobial activity of cefoperazone-sulbactam tested against Gram-negative organisms from Europe, Asia-Pacific, and Latin America","volume":"91","author":"Sader","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106045","article-title":"In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017","volume":"56","author":"Stone","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.05.007","article-title":"Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012\u20132016","volume":"96","author":"Stone","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0014","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/jac\/dkaa089","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017","volume":"75","author":"Stone","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115553_bib0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889321002455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889321002455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:56:46Z","timestamp":1760003806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889321002455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0732889321002455"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115553","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftazidime-avibactam and comparators against bacterial isolates collected in South Korea as part of the ATLAS global surveillance program (2016\u20132018)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115553"}}